(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 53.63% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.99%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.77%.
Taysha Gene Therapies's revenue in 2025 is $6,310,000.On average, 16 Wall Street analysts forecast TSHA's revenue for 2025 to be $2,101,235,510, with the lowest TSHA revenue forecast at $1,151,009,205, and the highest TSHA revenue forecast at $4,314,230,125. On average, 14 Wall Street analysts forecast TSHA's revenue for 2026 to be $1,141,422,027, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $4,314,230,125.
In 2027, TSHA is forecast to generate $8,452,330,093 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $26,529,091,275.